Protara Therapeutics, Inc. Cash Flow Statement
TARA|3 years of annual SEC 10-K data (FY2014-FY2016)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$10M
FY2016
Free Cash Flow
-$10M
FY2016
Capital Expenditures
$51,000
Cash used for long-term assets
Dividends Paid
N/A
FY2016
Protara Therapeutics, Inc. used $10M in operating cash flow and negative free cash flow of $10M in FY2016.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
- Accrual-heavy earnings: Net income significantly exceeds operating cash flow
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2016 | FY2015 | FY2014 |
|---|---|---|---|
| Net Income | -$3.3M | -$7.9M | -$8.0M |
| Depreciation & Amortization | $30.0K | $27.0K | $57.0K |
| Operating Cash Flow | -$10.0M | -$6.7M | -$8.2M |
| Capital Expenditures | $51.0K | $10.0K | $67.0K |
| Free Cash Flow | -$10.0M | -$6.7M | -$8.3M |
| FCF Margin | -340.6% | -226.1% | -281.6% |